Findings in AI-treated ER+ cancers are complicated by the induced increase in circulating and intratumoral androgens [196], and some metastatic AI-resistant ER+ cancers with mESR1 exhibited increased AR expression/and target genes [107]. The gene discussed is AR; the disease is cancer.